Grant: Idea to Innovation
Ryerson University
$125,000.00
3D quantum biosensor for multiple cancer screening and early diagnosis
FY 2021-22
Summary
Blood plasma has long been considered an ideal approach for screening multiple cancer types for its noninvasive nature. However, blood-based tests suffer poor diagnostic accuracy due to the low concentration of tumor-associated molecules. There are few commercially available blood-test kits for cancer screening, and the accuracy is far from satisfactory. The applicants invented a quantum-dots sensor enhanced Raman biomolecular analysis tool, sensitive enough to probe multiple biomarkers directly from blood plasma with high repeatability. With a single blood test, a complete profile of cancer, including the presence of cancer, the primary location of the tumor, quantification of metastasis, and progression, can be reported with a computerized diagnosis. Preliminary experiments have classified cancer types with a sensitivity of 83% ~100% and specificity of 80% ~ 100%, dependent on the type of biomarker. Cancer progression to nodes was predicted with a specificity of 92%. We believe that diagnostic accuracy can be raised close to 100% by integrating multiple biomarkers into the diagnosis algorithm. This project aims to develop the quantum-dots sensor enhanced Raman analyzer into a viable clinical tool for cancer screening/early diagnosis. The outcome of this project is a quantum biosensor aided microscopy-based blood test that is easy to use, cost-effective and is applicable towards multiple cancer types.The proposed blood test can report a complete tumor profile within an hour after blood withdrawal. With high accuracy, low cost, short turnaround, easy operation, and applicability to multiple cancer types, this strategy will be readily implemented in the clinical setting. It can be used for screening/early diagnosis as well as to provide guidance for clinical intervention. This ground-breaking technology potentially will lead to a universal cancer diagnosis test that applies to half of all cancer cases, increase cancer screening participation rate, and provide a screening method for cancer types that currently cannot be screened.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
561741-2021
Name nom
Venkatakrishnan, Krishnan
Department département
Mechanical and Industrial Engineering
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1
Partie
1
Nb partie
1
Application title
3D quantum biosensor for multiple cancer screening and early diagnosis
Keyword
NSERC
Application summary
Blood plasma has long been considered an ideal approach for screening multiple cancer types for its noninvasive nature. However, blood-based tests suffer poor diagnostic accuracy due to the low concentration of tumor-associated molecules. There are few commercially available blood-test kits for cancer screening, and the accuracy is far from satisfactory. The applicants invented a quantum-dots sensor enhanced Raman biomolecular analysis tool, sensitive enough to probe multiple biomarkers directly from blood plasma with high repeatability. With a single blood test, a complete profile of cancer, including the presence of cancer, the primary location of the tumor, quantification of metastasis, and progression, can be reported with a computerized diagnosis. Preliminary experiments have classified cancer types with a sensitivity of 83% ~100% and specificity of 80% ~ 100%, dependent on the type of biomarker. Cancer progression to nodes was predicted with a specificity of 92%. We believe that diagnostic accuracy can be raised close to 100% by integrating multiple biomarkers into the diagnosis algorithm. This project aims to develop the quantum-dots sensor enhanced Raman analyzer into a viable clinical tool for cancer screening/early diagnosis. The outcome of this project is a quantum biosensor aided microscopy-based blood test that is easy to use, cost-effective and is applicable towards multiple cancer types.The proposed blood test can report a complete tumor profile within an hour after blood withdrawal. With high accuracy, low cost, short turnaround, easy operation, and applicability to multiple cancer types, this strategy will be readily implemented in the clinical setting. It can be used for screening/early diagnosis as well as to provide guidance for clinical intervention. This ground-breaking technology potentially will lead to a universal cancer diagnosis test that applies to half of all cancer cases, increase cancer screening participation rate, and provide a screening method for cancer types that currently cannot be screened.
